References
- Livermore DM. Clinical significance of beta-lactamase induction and stable derepression in Gram-negative rods. Eur J Clin Microbiol 1987; 6: 439–45.
- Sanders CC, Sanders WE Jr. Beta-lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15: 824–39.
- European Study Group on Antibiotic Resistance. Resistance to beta-lactam antibiotics in septicemia isolates from twenty-nine European Laboratories. Eur J Clin Microbiol 1987; 6 : 515–20.
- Sanders CC. Cefepime: The next generation? Clin Infect Dis 1993; 17: 369–79.
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bac-teria that grow aerobically; Approved Standard M 7-A3. National Committee for Clinical Laboratory Standards, Villanova, PA, 1993.
- Watanabe NA. Newer antipseudomonal cephalosporins. J Chemother 1996; 8, (Suppl 2 ): 48–56.
- Thomsberry C, Brown SD, Yee YC, Bouchillon SK, Marler JK, Rich T. In-vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother 1993; 32 (Suppl B): 31-53.
- Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-produc-ing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study. Diagn Microbiol Infect Dis 1994; 19: 33–38.
- Gradelski E, Fung-Tomc J, Huczko E, Kessler RE. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother1993; 32 (Suppl B): 75-80.
- Pechere J-C, Vladoianu TR. Development of resistance during ceftazidime and cefepime therapy in a murine peri-tonitis model. J Antimicrob Chemother 1992; 29: 563–73.